Table 3 Mendelian randomisation analysis for estrogen-receptor-positive and negative breast cancer risk

From: Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation

 

ER+ breast cancer

ER− breast cancer

Exposures

BCAC

FinnGen

BCAC

FinnGen

Protein

beta

pval

beta

pval

beta

pval

beta

pval

CD160

−0.08

5.10E-04

−0.14

6.90E-03

−0.06

9.30E-02

−0.07

2.80E-01

DNPH1

0.08

6.20E-06

0.07

8.80E-02

0.09

6.00E-04

0.05

3.40E-01

LAYN

0.12

5.50E-04

0.13

1.20E-01

0.12

2.60E-02

0.17

1.00E-01

LRRC37A2

−0.04

1.80E-06

−0.06

3.50E-02

−0.04

7.90E-03

−0.01

8.30E-01

TLR1

0.07

1.60E-04

0.11

4.10E-02

0.09

2.30E-03

0.11

9.40E-02

  1. Exposures indicate the protein that was tested. The nsnp indicates the number of instrumental variables (variant associated with protein level) used in the Mendelian randomisation analysis. The beta value is the Mendelian randomisation causal estimate. The causal estimates shown are Wald ratios, which were calculated for each instrumental variable as the beta-value for breast cancer risk divided by the beta-value for the protein level. To estimate two-sided p-values, the Wald ratio standard error was first calculated as the standard error for breast cancer risk divided by the beta-value for the protein level whereupon the z-score was calculated, and the p-value computed from standardised normal distribution at each tail. BCAC stands for data from the Breast Cancer Association Consortium2.
Back to article page